G lioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Macrophages (MFs) and microglia constitute the dominant tumor-infiltrating immune cells. MFs/microglia that are capable of phagocytosis, 1 antigen processing and presentation, 2 cytotoxicity, and the promotion of inflammation 3 are designated M1. However, upon recruitment into the tumor microenvironment by chemoattractants such as CC chemokine ligand 2 (CCL2) 4, 5 and soluble colony-stimulating factor 1 (sCSF-1), 6, 7 MFs/microglia become immunosuppressive 8 -10 as designated as M2 and are unable to produce proinflammatory cytokines, induce effector T-cell anergy, demonstrate impairments in cytotoxicity 2,11 -13 , and induce Tregs. 14 Tumor-associated MFs are related to myeloidderived suppressor cells, which have known immunosuppressive properties 15 ; the tumor-associated MF probably represents a more mature subset of this cell population. 16 Tumor-associated M2 MFs have been shown to promote cancer by secreting proangiogenic factors and enhancing invasion 10, 17 mediated by the production of soluble factors such as transforming growth factor-b (TGF-b), 18 interleukin (IL)-1, 19 vascular endothelial growth factor, and matrix metallopeptidase-9. 20 The presence of MFs correlates with poor prognosis in a variety of malignancies, 21 and polymorphism in the gene CX3CR1, which plays a role in MF and microglial mobilization and migration, was found to potentially be associated with differential survival in patients with GBM. 22 Thus, it appears that malignant gliomas actively recruit microglia and MFs to the tumor site and induce them to adopt tumor-supportive phenotypes capable of mediating immunosuppression and promoting invasion. The mechanisms and participating cell populations that are mediating immunosuppressive MFs/microglia have not been fully established.
Malignant gliomas contain glioma cancer stem cells (gCSCs) that are a heterogeneous population of multipotent undifferentiated cells with the capacity for selfrenewal and are able to form neurospheres that are nonadherent in vitro, are highly tumorigeneic, 23 and can recapitulate the characteristics of malignant gliomas. 24 We have recently shown that gCSCs are powerful mediators of immunosuppression of the adaptive immune system, specifically T-cell responses. 25 These processes are dependent on the phosphorylated signal transducer and activator of transcription 3 (p-STAT3) pathway, 26 which has been previously been demonstrated to be a key pathway in cancer-mediated immune suppression 27 and is overexpressed in most cancers including gliomas. 28 STAT3 induces a variety of transcriptional factors that propagate tumorigenesis 29 and upregulate tumormediated immunosuppressive factors.
27,30
The STAT3-regulated tumor-secreted factors then activate STAT3 in diverse immune cells, including both innate immune cells such as MFs and T cells, 31 resulting in global immune suppression. 31 -34 When p-STAT3 is blocked in the gCSCs, cell proliferation is inhibited, neurosphere formation is impaired, the CD133-positive (CD133+) cells are depleted, 35 and the gCSC-mediated immunosuppression is blocked. 26 Additionally, using cytokine microarray analysis, we found that the gCSCs 25 were making MF inhibitory cytokine-1 (MIC-1), a member of the TGF-b super family, 36 which has been shown to be produced by glioblastoma cells 37 and found to be elevated in the cerebrospinal fluid of GBM patients, with higher levels associated with poorer outcome. 38 We have therefore hypothesized that the gCSCs can mediate innate immune suppression, possibly secondary to MIC-1, which can be reversed with STAT3 blockade. In this manuscript, we demonstrate that gCSCs induce MFs derived from peripheral blood monocytes, the myeloid precursors to normal and tumor-infiltrating microglia/ MFs, 39 to an immunosuppressive phenotype that is partially reversed with STAT3 blockade.
Material and Methods

Antibodies and Reagents
Tissue culture grade monoclonal antibodies to CD3 (OKT3) and CD28 (28.6) were obtained from eBioscience. There are no commercially available specific inhibitors of MIC-1. WP1066 was synthesized and supplied by Waldemar Priebe and was stored as a 10-mM stock solution in dimethyl sulfoxide and diluted with phosphate-buffered saline (PBS) when used. Doses of 2 mM WP1066 were used, which is within the physiological dose range that can be achieved in vivo. 40 For flow cytometry, antibodies against CD11b and CD45 labeled with phycoerythrin (PE), fluorescein isothiocyanate (FITC), or allophycocyanin, and corresponding IgG 1 isotypes were obtained from BD Pharmingen. CD133 antibody was obtained from Miltenyi Biotech, and p-STAT3 antibody and the corresponding IgG 2 isotypes were obtained from eBiosciences. ELISA kits for IL-10, TGF-b, sCSF-1, TNF-a, and MIC-1 were obtained from R&D Systems. ELISA antibodies for IL-23 were obtained from eBiosciences. Appropriate isotype controls were used for each antibody.
Human Tissues
Tumor tissues from newly diagnosed GBM patients were obtained from surgery specimens and were graded pathologically according to the World Health Organization's classification system by a neuropathologist. Normal brain specimens were obtained from surgeries for extra-axial tumors (such as meningioma) where the surgical approach to access the tumor required the resection of a portion of overlying normal brain. All specimens were processed within 4 hours after resection. Each patient provided a written informed consent for tumor tissues, and this study was conducted under protocol #LAB03-0687, which was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center.
Human gCSC Derivation
The gCSCs were derived as described previously. 41 The gCSC may express CD133, 42 although this is not a definitive marker of stem cells. 43 -45 There is no consensus on a definitive marker that can be used to determine "purity"; therefore, the characterization of the gCSC population was based on the criterion of in vivo tumorigenic potential, pluripotent potential, limiting dilution assays, and cytogenetic characterization, 41 which is consistent with our previously published reports. 25, 26 After primary sphere formation was noted, sphere cells were dissociated for the characterization of the properties that distinguish gCSCs such as cell self-renewal, differentiation, and tumorigenesis. Supernatants from the gCSCs were collected and stored at 2208C for use as a conditioned medium and ELISA analysis. The frequency of occurrence of gCSCs isolated from GBM tumors was in the range 0.5% -10% based on the observed CD133 expression. Doubling time for the gCSCs was in the range of 2-4 days. Using limiting dilution analysis, neurosphere formation occurred at the following frequencies: 1 of 16 for gCSC1, which had 4% of cells expressing CD133+; 1 of 3 for gCSC2, which had 14% of cells expressing CD133+; 1 of 6 for gCSC3, which had 79% of cells expressing CD133+; and 1 of 9 for gCSC4, which had 21% of cells expressing CD133+. Neurospheres of similar size could be reformed after placing the parental neurosphere into single-cell suspension for at least 20 passages, demonstrating their self-renewal and proliferative properties. Cytogenetic testing of the neurospheres indicated that the gCSCs were of glioma tumor origin and not invading neural progenitor cells based on the numerical and structural chromosomal aberrations of chromosomes 1 and 9. Furthermore, all 4 gCSCs expressed the repressor element 1-silencing transcription factor (REST). 46 The gCSCs were cultured in vitro with the neurosphere medium consisting of Dulbecco's modified Eagle's medium/F-12 medium containing 20 ng/mL of both epidermal growth factor and fibroblast growth factor 2.
CD133 Depletion of Bulk GBM
Single-cell suspensions of fresh primary GBM surgical specimens were prepared by mechanical dissociation and digestion with a type I collagenase (Sigma) for 1 hour at 378C. Cells were isolated on a 44%/66% Percoll gradient, and CD133+ cells were depleted by magnetic separation using CD133 microbeads as per the manufacturer's instructions (Miltenyi Biotec). CD133 depletion was verified by flow cytometry. Bulk and CD133-depleted tumor cells were cultured at 1 × 10 6 cells/mL in the neurosphere medium for 72 hours in a humidified atmosphere of 95% air/5% CO 2 before supernatants were collected for use as experimental controls.
Human Peripheral Blood Mononuclear Cells and Differentiation of Monocyte-Derived MFs
Peripheral blood mononuclear cells (PBMCs) were prepared from healthy donor blood (Gulf Coast Blood Center) by centrifugation on a Ficoll-Hypaque density gradient (Sigma-Aldrich). Monocytes were purified using CD14 microbeads according to the manufacturer's directions (Miltenyi Biotec). Monocytes were cultured for 5 days in the RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 50 U/mL granulocyte-macrophage colony-stimulating factor (GM-CSF; eBiosciences) in order to induce differentiation into MFs 47 at 378C in a humidified atmosphere of 95% air/5% CO 2 .
Isolation and Culture of Microglia
Microglia, the predominant immune cells in the CNS, 17 , 48 are MFs. 49 Although murine microglia can be distinguished from MFs based on CD45 expression, 50 in humans the distinction is far more ambiguous, and to date, no single histological marker has been described that can reliably distinguish microglia from MFs in human gliomas. Thus, these cells were purified using a Percoll gradient as we have described previously. 12 The microglia/MFs were collected from the 1.03 (g/mL)/1.065 (g/mL) and 1.065 (g/mL)/1.072 (g/mL) Percoll density layer interfaces, and their purity was ascertained using flow cytometry for the detection of CD45 and CD11b. Purified microglia/MFs were cultured in the RPMI 1640 medium supplemented with 10% FBS and 50 U/mL GM-CSF for 24 -48 hours prior to further experimentation.
Treatment of MFs with Medium Conditioned by gCSCs
Normal microglia or MFs were each cultured for 48 hours in a medium previously conditioned by bulk GBM supernatants in the neurosphere medium, bulk GBM supernatants with CD133+ depletion in the neurosphere medium, gCSCs, neurosphere medium, or neurosphere media with the addition of MIC-1. Cells were harvested, and surface marker expression was analyzed by flow cytometry. The culture supernatant was collected and analyzed with ELISA.
Flow Cytometry
Purity of the MFs and microglia after isolation was tested using FITC-conjugated anti-CD45 and PE-conjugated anti-CD11b, whereas the intracellular staining of p-STAT3 was done using PE-conjugated anti-p-STAT3, along with the corresponding IgG 1 or IgG 2 isotypes. Flow cytometry acquisition was done with a FACSCaliber (Becton Dickinson), and data analysis was performed using FlowJo software (TreeStar). Live cells were gated using forward and side scatters, and positive staining was determined using a threshold of .1% on the isotype sample.
ELISA Measurement of Cytokines in Medium Conditioned by gCSCs
The supernatant medium conditioned by gCSCs was measured for cytokine concentrations using ELISA kits as described (R&D Systems). The supernatants were collected after 5 days in culture and stored at 2208C. For ELISA tests, the supernatants were added in duplicate to appropriate coated plates. After the plates were washed, horseradish peroxidase-conjugated detection antibody was added. The substrate used for color development was tetramethylbenzidine. The optical density was measured at 450 nm with a microplate reader (Spectra Max 190; Molecular Devices), and chemokine concentrations were quantified with SoftMax Pro software (Molecular Devices). The detection limits for sCSF-1 were 16 pg/mL; for MIC-1, 8 pg/ml; for TNF-a, 31 pg/mL; for IL-23, 31 pg/mL; for IL-10, 16 pg/mL; and for TGF-b1, 31 pg/mL.
Cell Migration Assay
Cell migration assay kits (Cell Biolabs) were obtained and migration assays conducted as per the manufacturer's instructions. The culture well inserts (provided with a membrane pore size of 5 mM) were seeded with CD14+ human monocytes and placed in 24-well culture plates containing either neurosphere medium (as the negative control), bulk GBM supernatants in neurosphere medium, bulk GBM supernatants with CD133 depletion in neurosphere medium, gCSC-conditioned medium, or a medium containing 10 ng/mL sCSF-1 (positive control). After overnight culture, all the cells that migrated through the membrane into the experimental medium were collected, pelleted with centrifugation, resuspended in a unit volume, and manually counted using a hemocytometer. Total migration was calculated as a percentage of the negative control.
T-Cell Proliferation Assay
T-cell proliferation was determined using a carboxyfluorescein diacetate succinimidyl ester (CFSE)-based assay, 51 which we have used previously. 12, 25, 26, 40 In brief, healthy donor PBMCs were labeled with 2 mM CFSE for 5 minutes at room temperature in PBS, and then the reaction was quenched with the RPMI 1640 medium with 10% FBS for 10 minutes at 378C. The 48-well culture plates were incubated with 1 mg/mL anti-CD3/ anti-CD28 in PBS for 1 hour. About 2 × 10 5 PBMCs/ well were plated in the 48-well plates with pre-bound anti-CD3/anti-CD28, and the conditioned medium from gCSCs and MFs was added to the stimulated PBMCs. The cells were harvested for analysis after 96 hours.
Phagocytosis Assay
After incubation for 48 hours with experimental supernatants as described above, the microglia or MF cell viability was assessed by Trypan Blue exclusion, and live microglia or MFs were transferred to a 96-well plate at a concentration of 1.0 × 10 5 cells/well and incubated at 378C in a humidified atmosphere containing 95% air/ 5% CO 2 for 1 hour to allow the cells to adhere. The cells were then incubated with pHrodo Escherichia coli BioParticles (Invitrogen) suspended in PBS for 2 hours at 378C at atmospheric CO 2 levels. The supernatant containing the bioparticles was then removed and the cells incubated for 15 minutes with DAPI (Vector Laboratories) at room temperature in order to identify the nuclei. In order to quantify phagocytosis, digital images were taken using fluorescence microscopy (×20 magnification) under identical camera exposure and compensation settings for control and experimental conditions. Each image was analyzed using Adobe Photoshop CS software. Background fluorescence in the cell-free regions for each image was determined. The fluorescence intensity in each individual cell was then measured and corrected for the background. The overall level of phagocytosis was expressed as mean fluorescence intensity per cell. Percent phagocytosis levels relative to the control (neurosphere medium alone) were calculated for each experimental condition.
STAT3 siRNA Transfection
To knockdown STAT3 gene expression, STAT3 small interfering RNA (siRNA) was transfected into gCSC lines as described by the manufacturer (Santa Cruz Biotech). Briefly, 0.5 × 10 6 gCSCs per well were seeded in a 6-well plate. siRNA duplex solution (1 mg STAT3 siRNA or 2 controls of siRNA A and B) in 100 mL of siRNA transfection medium was prepared and gently mixed with siRNA transfection reagent in 100 mL of siRNA transfection medium, incubated for 45 minutes at room temperature, and then diluted to a final volume of 1 mL and overlayed on the cells. The cells were incubated for 5 hours at 378C, followed by the addition of 1 mL of the neurosphere medium and incubation overnight. The medium was then replaced with a fresh neurosphere medium, and the cells were incubated for an additional 48 hours.
pSTAT1 Western Blot
After exposure to the gCSC-conditioned medium and other experimental conditions for 48 hours, the MFs were harvested, pelleted by centrifugation, and rinsed with ice-cold PBS at 380 g for 5 minutes. The cells were lysed for 30 minutes in an ice-cold lysis buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM EDTA) containing 1% Triton X-100 and phosphatase and protease inhibitors (Sigma-Aldrich). The lysates were centrifuged at 14 000 rpm for 10 minutes at 48C. The supernatants were collected and quantified for the protein content. Equal amounts of proteins (20 mg) were electrophoretically fractionated in 8% sodium dodecyl sulfate-polyacrylamide gels, transferred to nitrocellulose membranes, and subjected to immunoblot analysis with specific antibodies against p-STAT1 (Tyr701; Cell Signaling Technology, Inc.). Autoradiography of the membranes was performed using Amersham ECL Western-blotting detection reagents (Amersham Biosciences).
Statistical Analysis
The distribution of each continuous variable was summarized by its mean, standard deviation, and range. The Wilcoxon rank-sum test was conducted for the comparison of any 2 groups. The corresponding nonparametric sign-rank test for paired t-test was used to compare experimental and control groups that were matched. Owing to the exploration nature of this study, type I error was not adjusted in cases of multiple comparisons. All computations were carried out in SAS version 9.1. Error bars represent the standard deviation.
Results
gCSCs Secrete Cytokines that Regulate Innate Immunity
We have previously isolated gCSCs at the time of surgery from patients newly diagnosed with GBM and shown that these cells form neurospheres, are capable of multipotential differentiation, and can induce tumors at low doses. 25 The gCSCs (n ¼ 4) produced TGF-b1 (range: 8. 
gCSCs Induce Migration of Monocytes
To ascertain whether the gCSCs can induce migration of the monocytes, the medium conditioned by single-cell suspensions from newly diagnosed GBM, single-cell suspensions from newly diagnosed GBM depleted of CD133+ cells, and the gCSCs were tested in a cell migration chemotaxis assay (Fig. 1A) . All four gCSCs potently induced migration (range, 168 + 26%-362 + 33% relative to controls; P ¼ .03) of the monocytes in a manner similar to our positive control medium containing sCSF-1 (152 + 23% -261 + 27% Fig. 1 . Attraction and phenotype alteration of monocytes by gCSCs. Monocytes upon exposure to the gCSC-conditioned medium (n ¼ 4) demonstrated (A) increased migration in a cell-migration chemotaxis assay compared with both control neurosphere medium alone and supernatants from bulk and CD133+ depleted primary GBM and (B) an increase in p-STAT3 expression, as shown by flow cytometry, relative to control monocytes exposed to neurosphere medium alone. (C) Western blot showing that p-STAT1 expression was decreased within monocytes and MFs by gCSC-conditioned medium and MIC-1, and that this was partially reversed by p-STAT3 blockade with WP1066 (WP ¼ 2 mM WP1066). C is control neurosphere medium. relative to control; P ¼ .03), a known chemoattractant for monocytes. The amount of sCSF-1 produced by each gCSC line correlated in a nonlinear fashion with the degree of monocyte migration induced. Whereas the single-cell suspensions from the newly diagnosed GBM patients, including those depleted of CD133+ cells, failed to significantly induce migration of monocytes in comparison to the control neurosphere medium.
gCSCs Induce p-STAT3 Expression in Monocytes
When monocytes were cultured in the gCSCconditioned medium, the morphology of the monocytes changed to become flattened, adherent, and irregularly shaped, with cell processes that were consistent with MF morphology. Incubation of the monocytes for 24 hours with the conditioned medium from each of the respective gCSC lines (n ¼ 4) markedly induced an increase in the expression of p-STAT3 (Fig. 1B) relative to control monocytes (n ¼ 2) incubated in the neurosphere medium alone (range: 15.5%-29.0%; mean 21.4 + 5.6%, compared with 5.5%-9.0%; mean 7.3 + 2.4%).
gCSCs Down Modulate p-STAT1 Expression in MFs
Proinflammatory M1 MFs express p-STAT1, and upon polarization toward an immunosuppressive phenotype (M2), show a decrease in the expression of p-STAT1 with a relative increase in the expression of p-STAT3. 52 Therefore, we assessed the expression of p-STAT1 in MFs after exposure to the gCSC-conditioned medium. The gCSC supernatants down modulated the expression of p-STAT1 in MFs relative to controls treated with the neurosphere medium alone, and this down modulation was partly reversed if the MFs were also treated with WP1066 (Fig. 1C) .
gCSCs Inhibit MF and Microglia Phagocytosis
To evaluate the role of gCSCs on MF function, human monocytes were isolated from peripheral blood of normal donors and induced to differentiate into MFs in vitro. 47 Phenotypic markers indicated at least .95% purity based on the CD14
The medium cultured by all of the gCSC supernatants inhibited phagocytosis by the MFs (representative example shown in Fig. 2A ,i and ii; gCSC1, 59.9% + 2.2% of neurosphere medium alone, P ¼ .05, n ¼ 3; gCSC2, 44.9% + 4.5%, P ¼ .03, n ¼ 4; gCSC3, 58.6% + 17.4%, P ¼ .03, n ¼ 4; gCSC4, 63.7% + 19.1%, P ¼ .03, n ¼ 4). Whereas bulk primary GBM supernatant (104.5% + 2.5%, P ¼ .31, Fig. 2A ,iii) and CD133+ depleted primary In contrast, (iii) bulk primary GBM supernatant and (iv) CD133+ depleted primary GBM supernatant did not inhibit phagocytosis. Furthermore, representative microscopy demonstrates that phagocytosis is inhibited in MFs exposed to (v) 10 ng/mL MIC-1. MF nuclei were stained with DAPI (blue). A similar inhibition of phagocytosis by the gCSC-conditioned medium was seen in normal microglia (Supplementary Fig. 1 ). (B) T-cell proliferation was inhibited by MFs treated with gCSC-conditioned medium (n ¼ 4) compared with MFs treated with neurosphere medium alone. When MFs were pulsed with gCSC-conditioned medium (n ¼ 4), inhibition of T-cell proliferation was maintained even after gCSC-conditioned medium was removed and replaced with a fresh growth medium. Inhibition of T-cell proliferation is expressed as a percent positive control neurosphere medium alone (*significantly different from MFs alone ; P , .05). (C) Representative CFSE histograms comparing the inhibition of T-cell proliferation between MFs alone and MFs pulsed with the gCSC-conditioned medium.
GBM (99.2% + 4.5% of neurosphere medium alone, Fig. 2A,iv) had no appreciable effect. The degree of phagocytosis inhibition did not correlate with CD133 expression. Similar results were found with human microglia in which the gCSCs inhibited phagocytosis to 57% -62% (n ¼ 2) in comparison to the neurosphere medium alone (Supplementary Fig. S1 ).
gCSCs Induce MFs to Produce Immunosuppressive Cytokines
To ascertain if the gCSCs were triggering the production of known MF-elaborated immunosuppressive cytokines such as TGF-b1, 14 IL-10, 53 and IL-23, 54 the MFs were treated with a medium conditioned by the gCSCs and compared with control MFs treated with the neurosphere medium alone. The control MFs (n ¼ 3) elaborated TGF-b1 (range: 200 -1280 pg/10 6 cells/24 h) and IL-10 (range: 40 -280 pg/10 6 cells/24 h) but not IL-23. IL-10 production was enhanced by a medium conditioned by all of the gCSC lines ( 
gCSCs Potentiate MF and Microglia Inhibition of T-cell Proliferation
Because the gCSCs induce the MFs to increase the production of immunosuppressive cytokines, we next wanted to ascertain whether these cytokines were functionally active as determined by their ability to inhibit T-cell proliferation. Exposure of the MFs to the gCSC-conditioned medium (n ¼ 4) significantly increased the ability of the medium conditioned by MFs and microglia to inhibit T-cell proliferation by 68.0% -77.5% (P ¼ .03) relative to the culture medium from MFs treated with a control neurosphere medium, which did not significantly affect the T-cell proliferation (Fig.  2B  and  C) . Because the gCSC-conditioned medium alone can inhibit T-cell proliferation (range: 43.5%-70.3% of the neurosphere medium alone), to confirm that the gCSC-conditioned MFs were contributing to the inhibition of T-cell proliferation, the MFs were washed and the medium was replaced after the MFs were exposed to the gCSC-conditioned medium. The supernatant medium from these gCSC-pulsed MFs retained the ability to inhibit T-cell proliferation (range: 48.5% -57.3% relative to MFs treated with the control neurosphere medium, P ¼ .03) even in the absence of any factors directly produced by gCSCs. Similarly, the medium conditioned by normal microglia without exposure to the gCSC-conditioned medium did not significantly inhibit T-cell proliferation but did inhibit T-cell proliferation by 75.2% -75.5% (n ¼ 2) after exposure to the gCSC-conditioned medium.
The Immunosuppressive Role of the p-STAT3 Pathway in gCSC-Mediated MF Immunosuppression
To determine if p-STAT3 blockade can change the innate immunosuppressive functions of the gCSCs, the gCSCs were treated with either the STAT3 siRNA or the small molecule inhibitor WP1066 at levels that do not affect cell viability. 26 The induction of IL-10 production in MFs by the gCSC-conditioned medium was reduced when p-STAT3 was inhibited in gCSCs by WP1066 (0.5 + 0.1-fold control) and STAT3 siRNA (0.7 + 0.1-fold control) compared with untreated gCSCs (1.7 + 0.1-fold control) but not by either of the 2 control siRNAs (2.5 + 0.2-fold and 3.8 + 0.1-fold control, respectively; Fig. 3A) . In contrast, IL-23 and TGF-b1 induction in the MFs was not decreased to a statistically significant degree when p-STAT3 was inhibited in gCSCs (data not shown).
To determine if the inhibition of phagocytosis by gCSCs is mediated by the p-STAT3 pathway, 2 gCSC lines were treated with WP1066 and siRNA, and MFs were exposed to the resulting conditioned medium (Fig. 3B) . For both gCSC lines, the inhibition of phagocytosis by the gCSCs (range: 44.9% -67.7%) was reversed by both WP1066 (range: 75.1% -110.6%) and STAT3 siRNA (range: 95.2% -100.2%) but not by either of the two different control siRNAs (ranges: 16.9%-57.8% and 44.2% -66.8%, respectively).
The Role of gCSC MIC-1 in Immunosuppressive MFs
As described above, we found that gCSCs produced MIC-1 at a physiological range of 0.16 -47.7 ng/mL and therefore evaluated the role that MIC-1 played in the ability of gCSCs to induce immunosuppressive MFs, by treating monocytes and MFs with the neurosphere medium containing MIC-1 at doses within this physiological range. At a dose of 10 ng/mL (n ¼ 2), MIC-1 had no effect on the expression of cell surface markers by monocytes (data not shown) but did marginally increase the expression of p-STAT3 (range: 8.9% -13.8%; mean 11.4 + 3.5% relative to the neurosphere medium control; Fig. 1C ). MIC-1 also decreased the expression of p-STAT1 in MFs (Fig. 1D) . Exposure of either the MFs or microglia to MIC-1 resulted in a marked inhibition of phagocytosis (62.8% + 7.3%, P ¼ .05, n ¼ 3; Fig. 2B,v) . Secretion of both TGF-b1 and IL-10 (but not of IL-23) was increased by MIC-1 (Table 2 ) but generally to a degree less than that observed for the gCSC-conditioned medium. STAT3 blockade in the gCSCs also did not significantly reduce their production of MIC-1 (data not shown), suggesting that gCSCs may be able to induce immunosuppressive MFs/microglia via multiple pathways, some of which may be independent of gCSC p-STAT3 pathways.
Discussion
In this report, we demonstrate that the gCSCs contribute to the conversion of monocytes to an immunosuppressive MF/microglia (M2) phenotype by a variety of secreted factors. Previously, both glioma-elaborated CCL2 and sCSF-1 had been shown to recruit monocytes into the tumor microenvironment. Our ELISA data demonstrate that the gCSCs secrete these factors and that the gCSC-conditioned medium increases monocyte migration, indicating that the gCSCs are probably recruiting monocytes into the tumor microenvironment. Supportive of this contention is that the single-cell suspensions from the GBM, which contain a low frequency of gCSCs (1% -3% CD133 + cells), as anticipated, failed to significantly induce the migration of monocytes. We have also provided several pieces of evidence indicating that the gCSC is then polarizing the MF/microglia toward the immunosuppressive (M2) phenotype. First, based on Western blot analysis and intracellular cytokine staining, the gCSCs down modulated p-STAT1 and upregulated p-STAT3 within the monocyte population. These data are consistent with a previous report demonstrating upregulation of p-STAT3 in dendritic cells. 31 Furthermore, we demonstrated that the gCSC induces the MF to produce immunosuppressive cytokines that functionally inhibit T-cell proliferation and effector responses.
We also showed that gCSCs impede the phagocytosis ability of MFs/microglia. A reduction in phagocytic capacity does not necessarily imply an immunosuppressive phenotype, as M2 MFs can in some circumstances efficiently phagocytose, 55 which is not surprising given the normal physiological role of M2 MFs in debris scavenging. 56 Rather, the in vitro inhibition of phagocytosis of microbeads we demonstrate here may represent a direct suppression of M1 effector function, which may or may not be independent of a concurrent polarization toward the M2 phenotype. Thus, in addition to the inhibition of adaptive immune responses that we have shown previously, 25, 26 we find that gCSCs are additionally exerting immunosuppression of the innate immune system-the first report to date to our knowledge.
The gCSC induction of immunosuppressive cytokines by MFs was variable. For example, some gCSCs increased TGF-b1, whereas others induced IL-23. The magnitude of cytokine production also varied between MFs derived from different donors and as a result the increases in cytokine production did not reach statistical significance. However, in nearly all instances where a particular gCSC increased the production of a particular cytokine, an increase was seen with every donor MF tested supporting the contention of the gCSCs triggering MF elaborated immune suppressive cytokines. There is also the possibility, as some production of both IL-10 and TGF-b1 was observed consistently in control MFs, that constitutive immunosuppressive cytokine production by MFs may be more important in vivo than any further induced increases, with the recruitment of the MFs being the more important role of the gCSCs. However, we did find that supernatants conditioned by MFs exposed to gCSCs inhibited T-cell proliferation to a greater extent than MFs alone, which suggests that increases in MF cytokine production mediated directly by gCSCs does have physiological consequences.
Extrapolating the rates of cytokine production measured in vitro to in vivo cytokine levels is challenging since in vivo levels will be dependent on multiple factors, including cell densities, proximity of various cell types to one another, rates of efflux and elimination, multiple sources of production, and local environmental factors such as hypoxia to name a few. This caveat also applies to the physiological significance of the phagocytosis and T-cell proliferation inhibition. For example, serum levels of TGF-b1 in human GBM patients have been reported to be approximately 800 pg/mL 57 and murine intratumoral TGF-b1 levels to be around 60 pg/mg of total protein that correlated with a 2-fold increase in FoxP3+ Treg infiltration 58 . In terms of functionally relevant in vivo changes in cytokine levels, treatment that resulted in a significant inhibition of tumor growth in an animal model of lung cancer resulted in a 2-fold decrease in the intratumoral concentrations of both IL-10 and TGF-b1. 59 Given the paucity of correlative in vivo intratumoral data, the physiological relevance of changes in the various cytokines we observed in vitro is therefore indeterminate.
On the basis of the cytokine microarray data, we noted that the gCSCs produced abundant MIC-1 that was lost upon differentiation. 25 Furthermore, other studies have shown that MIC-1 is an inducer of STAT3 in neurons 60 and that MIC-1 exerts immunosuppressive effects on MFs. 36 We therefore investigated whether MIC-1 was specifically contributing to the gCSC-mediated M2 polarization of the MFs. We found that physiological doses of human recombinant MIC-1 were able to inhibit phagocytosis and upregulate IL-10 and TGF-b1. However, MIC-1 did not markedly increase p-STAT3 in MFs, down modulate the costimulatory molecules (data not shown) or induce the MF's ability to inhibit T-cell proliferation (data not shown). Furthermore, although physiological doses of MIC-1 did induce IL-10 and TGF-b, these were less than the amounts that were achieved with supernatants from the gCSCs, indicating that MIC-1 is not the sole contributor for M2 polarization. This indicates that there is a complex interplay between the gCSCs and the MF that involves both STAT3-dependent and -independent processes. Unfortunately, because there is no commercially available antibody that will specifically block human MIC-1, we were not able to ascertain the relative contribution of MIC-1 and other gCSC-secreted products controlling the M2 polarization.
On the basis of the cumulative data, we present the following schema: the gCSC is elaborating CSF-1 that recruits the monocyte into the tumor microenvironment. Then, a variety of gCSC-secreted products, including MIC-1, induce the polarization of the monocytes to the immunosuppressive (M2) MF. Upon polarization to the M2 phenotype, the MF then acts in a protumorigenic manner by enhancing invasiveness, increasing tumor angiogenesis, and potentiating tumor-mediated immunosuppression by a variety of secreted products such as IL-10, TGF-b, and IL-23, which would decrease Th1 skewing, decrease T-cell proliferation, and enhance Treg proliferation and recruitment (Fig. 4) .
Another limitation and concern with an analysis of gCSCs maintained in vitro is the fact that we have noted the immunological changes in these cells over time in culture. In order to negate this as much as possible, upon the initial isolation and characterization of these cells, we banked bulk gCSC-conditioned medium and used early passaged cells, but we have noted that with sequential passages the gCSCs become less immunosuppressive. Thus, our findings may underestimate the degree of gCSC-mediated immunosuppression that is exerted in vivo. Glioma cell lines that have lost their immunosuppressive capabilities over time may fail to recapitulate the level of immune suppression of de novo glioblastoma when used in animal models, and their response to immunotherapy may therefore not be reflective of the intrinsic in vivo biology. Thus, it will be essential for future research to delineate what factors of the native tumor microenvironment in which gCSCs are found, such as tissue hypoxia, are responsible for promoting and maintaining the immune suppressive phenotypes of these cells in vivo, and how they might be subject to therapeutic manipulation with agents such as hypoxia inducible factor-1a inhibitors.
In this current study, we saw paradoxical increases in IL-10 and IL-23 using control siRNA that may be secondary to the engagement of toll-like receptors (TLRs) expressed on the gCSCs. Typically, TLR agonists on monocytes and MFs would result in their subsequent activation and proinflammatory function; however, TLR agonists can further attenuate immune suppression after M2 polarization. 56,61 -65 It is therefore possible that TLR agonists may actually potentiate gCSC-mediated immune suppression and is also an area of future investigation. In addition to the gCSCs, another target cell that may be considered for therapeutic manipulation would be the immune suppressive MF/microglia, or its precursors, in order to counteract their tumor supportive activities with respect to immune suppression, 13 invasion, 17 and angiogenesis. 10 Therapeutic approaches could include inhibiting the polarization of the infiltrating MF to the M2 phenotype or the ability of either the MF or its circulating and bone marrow precursors to respond to gCSC signals, such that upon entry into the tumor microenvironment, these MFs do not become polarized toward the M2 immune suppressive and tumor supportive phenotype and instead toward the M1 phenotype that has antitumor activity. In order to ascertain the feasibility of this approach, it will be necessary to define the pathways in the MFs that are activated in response to gCSC signals.
The multimodal nature of glioblastoma-mediated immunosuppression has thwarted past attempts to treat this cancer with immunotherapy, wherein modulating any one or even several immune pathways proves ineffective because global immune suppression continues to be maintained by other redundant mechanisms. Because of the central role of gCSCs in glioblastoma initiation, progression, recurrence, resistance to chemotherapy and radiation, and immune suppression, the gCSC as an immune therapeutic target has recently garnered interest. 66 -68 The potential for success for such strategies will depend on whether the selfprotective immunosuppressive properties of gCSCs can be overcome such that these cells become exposed to immune recognition and vulnerable to immune clearance. 69 In this report, we demonstrate that the treatment of gCSCs with STAT3 siRNA or WP1066 restored phagocytosis and that the gCSC-exposed MFs were less inhibitory of adaptive immunity. Targeting the p-STAT3 pathway in the gCSCs represents a feasible therapeutic approach for the development of future novel therapies in the treatment of glioblastoma; however, this may not completely block the immunosuppressive functions of these cells, and other pathways are likely to be contributing to the gCSC-mediated immunosuppression. p-STAT3 blockade may be used alone (promoting the host immune system's own capacity for tumor clearance) or in combination with other modes of immunotherapy, and we have recently shown that p-STAT3 blockade enhanced IFN-a immunotherapy in a murine metastatic melanoma model. 70 Similar synergistic therapeutic combinations may hold promise for glioblastoma as well. However, even p-STAT3 does not appear to be the whole story in gCSC-mediated immune suppression, and it appears that p-STAT3 independent mechanisms of immune suppression also exist in parallel. For example, in this study, we observed that MIC-1-mediated suppression of MFs did not appear to be wholly related to p-STAT3 activation. Therefore, it will be necessary to identify and characterize other major transcriptional hubs like p-STAT3 that play roles in the mediation of multiple downstream immune modulatory pathways in order to appropriately formulate therapeutic immune strategies.
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